MyFinsight
Home
Blog
About
Net decrease in cash
and cash...
-$7,543,641
(12.10%↑ Y/Y)
Stock-based compensation,
including the issuance of...
$943,911
(-55.39%↓ Y/Y)
Accounts payable
$58,669
(108.93%↑ Y/Y)
Depreciation
$2,807
(-79.48%↓ Y/Y)
Acquired in-process
research and development...
$1,656
Net cash used in
operating activities
-$7,375,916
(14.25%↑ Y/Y)
Net cash provided by
financing activities
-$166,069
(-967.79%↓ Y/Y)
Net cash used in
investing activities
-$1,656
Canceled cashflow
$1,007,043
Other income
$408,728
Collaboration revenue
$243,745
Net loss
-$6,638,260
(50.47%↑ Y/Y)
Prepaids and other
current assets
$1,218,258
(153.01%↑ Y/Y)
Payment of financing
costs related to the...
$124,286
Proceeds from sale of
common stock, net of...
-$41,783
Purchase of in-process
research and development...
$1,656
Canceled cashflow
$652,473
Deferred collaboration
revenue
-$243,745
(42.17%↑ Y/Y)
Accrued expenses
-$162,255
(-111.19%↓ Y/Y)
Other assets
$120,441
Total research and
development expenses
$5,030,667
Total general and
administrative expenses
$2,255,603
Depreciation
$2,807
(-79.48%↓ Y/Y)
In-process research and
development
$1,656
Back
Back
Cash Flow
Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc. (COYA)
source: myfinsight.com